Thomas Heimann

Thomas Heimann is an analyst at HBM Partners, a firm specializing in healthcare investments. He has expressed concerns about the recent upheaval at the U.S. Food and Drug Administration (FDA), particularly regarding the significant staff layoffs that could impact the approval processes for new medications. Heimann has noted that the loss of experienced personnel from the FDA could lead to delays in the market entry of new drugs, especially those addressing unmet medical needs, thereby affecting the pharmaceutical industry at large.